Skip to main content

Table 5 Response by irAE and Disease Type

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Best Response mM mRCC
  irAE, n = 84 No irAE, n = 539 irAE, n = 46 No irAE, n = 873
Complete Response (CR) 5(6.0%) 23(4.3%) 3 (6.5%) 44(5.0%)
Partial Response (PR) 27 (32.1%) 89 (16.5%) 10 (21.7%) 153 (17.5%)
Stable Disease (SD) 29 (34.5%) 167 (31.0%) 19 (41.3%) 317 (36.3%)
Progressive Disease (PD) 19 (22.6%) 211 (39.1%) 13 (28.3%) 262 (30.0%)
Missing 4 (4.8%) 49 (9.1%) 1 (2.2%) 97 (11.1%)
CR + PR (n,%) 32 (38.1%) 112 (20.8%)
aP = 0.0058
13 (28.3%) 197 (22.6%)
aP = 0.5999
CR + PR+ SD (n, %) 61 (72.6%) 279 (51.8%)
bP = 0.0013
32 (69.6%) 514 (58.9%)
bP = 0.6263
  1. aFisher’s exact test comparing best response by irAE
  2. bFisher’s exact test comparing tumor control by irAE